Tibet Aim Pharm Inc (002826) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.109x

Based on the latest financial reports, Tibet Aim Pharm Inc (002826) has a cash flow conversion efficiency ratio of 0.109x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥87.55 Million ≈ $12.81 Million USD) by net assets (CN¥802.15 Million ≈ $117.38 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 002826 equity to assets ratio to measure how much of total assets are equity-financed.

Tibet Aim Pharm Inc - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Tibet Aim Pharm Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Tibet Aim Pharm Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.

Tibet Aim Pharm Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tibet Aim Pharm Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Viromed Medical AG DU:Q11	-0.038x
Unipar Carbocloro S.A SA:UNIP3	0.098x
Kneat.com Inc TO:KSI	-0.047x
Taiyuan Lionhead Cement Co Ltd SHG:600539	-0.034x
Frontera Energy Corp TO:FEC	0.129x
Albaraka Turk Katilim Bankasi AS IS:ALBRK	-0.403x
Levinstein Eng TA:LEVI	0.001x
Nanjing CEC Environmental Protect SHE:300172	-0.029x

Annual Cash Flow Conversion Efficiency for Tibet Aim Pharm Inc (2013–2025)

The table below shows the annual cash flow conversion efficiency of Tibet Aim Pharm Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see 002826 market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥816.02 Million ≈ $119.41 Million	CN¥123.72 Million ≈ $18.10 Million	0.152x	+1.31%
2024-12-31	CN¥745.58 Million ≈ $109.10 Million	CN¥111.57 Million ≈ $16.33 Million	0.150x	-32.74%
2023-12-31	CN¥750.06 Million ≈ $109.76 Million	CN¥166.88 Million ≈ $24.42 Million	0.222x	+143.77%
2022-12-31	CN¥750.00 Million ≈ $109.75 Million	CN¥68.45 Million ≈ $10.02 Million	0.091x	-39.99%
2021-12-31	CN¥720.11 Million ≈ $105.37 Million	CN¥109.52 Million ≈ $16.03 Million	0.152x	+2.73%
2020-12-31	CN¥687.15 Million ≈ $100.55 Million	CN¥101.74 Million ≈ $14.89 Million	0.148x	+63.10%
2019-12-31	CN¥652.17 Million ≈ $95.43 Million	CN¥59.20 Million ≈ $8.66 Million	0.091x	+321.64%
2018-12-31	CN¥618.40 Million ≈ $90.49 Million	CN¥13.31 Million ≈ $1.95 Million	0.022x	-83.16%
2017-12-31	CN¥604.53 Million ≈ $88.46 Million	CN¥77.29 Million ≈ $11.31 Million	0.128x	+24.19%
2016-12-31	CN¥555.44 Million ≈ $81.28 Million	CN¥57.18 Million ≈ $8.37 Million	0.103x	+186.07%
2015-12-31	CN¥248.25 Million ≈ $36.33 Million	CN¥-29.69 Million ≈ $-4.34 Million	-0.120x	-1080.84%
2014-12-31	CN¥179.12 Million ≈ $26.21 Million	CN¥2.18 Million ≈ $319.61K	0.012x	-98.33%
2013-12-31	CN¥71.66 Million ≈ $10.49 Million	CN¥52.24 Million ≈ $7.64 Million	0.729x	--

About Tibet Aim Pharm Inc

SHE:002826 China Drug Manufacturers - Specialty & Generic

Market Cap

$449.78 Million

CN¥3.07 Billion CNY

Market Cap Rank

#12648 Global

#3673 in China

Share Price

CN¥16.12

Change (1 day)

+0.06%

52-Week Range

CN¥15.01 - CN¥25.74

All Time High

CN¥32.76